CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 108 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $821,596 | +79.8% | 131,036 | 0.0% | 0.27% | +71.8% |
| Q3 2022 | $457,000 | +18.7% | 131,036 | 0.0% | 0.16% | +26.8% |
| Q2 2022 | $385,000 | -5.2% | 131,036 | 0.0% | 0.12% | +7.0% |
| Q1 2022 | $406,000 | -8.1% | 131,036 | 0.0% | 0.12% | +7.5% |
| Q4 2021 | $442,000 | -7.5% | 131,036 | 0.0% | 0.11% | -0.9% |
| Q3 2021 | $478,000 | -16.3% | 131,036 | 0.0% | 0.11% | -39.0% |
| Q2 2021 | $571,000 | -4.0% | 131,036 | 0.0% | 0.18% | -13.7% |
| Q1 2021 | $595,000 | -20.9% | 131,036 | 0.0% | 0.20% | -20.2% |
| Q4 2020 | $752,000 | -20.6% | 131,036 | 0.0% | 0.26% | +26.6% |
| Q3 2020 | $947,000 | +107.7% | 131,036 | 0.0% | 0.20% | +59.8% |
| Q2 2020 | $456,000 | +138.7% | 131,036 | 0.0% | 0.13% | 0.0% |
| Q1 2020 | $191,000 | -25.4% | 131,036 | 0.0% | 0.13% | +2.4% |
| Q4 2019 | $256,000 | -61.8% | 131,036 | 0.0% | 0.12% | -70.8% |
| Q3 2019 | $670,000 | -28.5% | 131,036 | 0.0% | 0.42% | +18.1% |
| Q2 2019 | $937,000 | -46.1% | 131,036 | 0.0% | 0.36% | -76.9% |
| Q1 2019 | $1,739,000 | +68.8% | 131,036 | 0.0% | 1.56% | +66.2% |
| Q4 2018 | $1,030,000 | -66.0% | 131,036 | -52.1% | 0.94% | -48.0% |
| Q3 2018 | $3,027,000 | -17.5% | 273,417 | 0.0% | 1.80% | -14.1% |
| Q2 2018 | $3,667,000 | +3.2% | 273,417 | 0.0% | 2.10% | -5.1% |
| Q1 2018 | $3,552,000 | -66.3% | 273,417 | -76.2% | 2.21% | -71.1% |
| Q4 2017 | $10,553,000 | -15.0% | 1,147,077 | -25.6% | 7.65% | -11.1% |
| Q3 2017 | $12,419,000 | +34.8% | 1,542,722 | -3.6% | 8.60% | +17.2% |
| Q2 2017 | $9,216,000 | +34.3% | 1,600,000 | 0.0% | 7.33% | +43.4% |
| Q1 2017 | $6,864,000 | +152.4% | 1,600,000 | 0.0% | 5.11% | +124.9% |
| Q4 2016 | $2,720,000 | -12.4% | 1,600,000 | 0.0% | 2.27% | -23.6% |
| Q3 2016 | $3,104,000 | +10.9% | 1,600,000 | 0.0% | 2.98% | +1.5% |
| Q2 2016 | $2,800,000 | +29.6% | 1,600,000 | 0.0% | 2.93% | +46.1% |
| Q1 2016 | $2,160,000 | -19.2% | 1,600,000 | 0.0% | 2.01% | +24.4% |
| Q4 2015 | $2,672,000 | -13.0% | 1,600,000 | 0.0% | 1.61% | -10.1% |
| Q3 2015 | $3,072,000 | – | 1,600,000 | – | 1.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,641,804 | $7,454,000 | 6.54% |
| COMMODORE CAPITAL LP | 2,983,513 | $13,545,000 | 5.40% |
| Foresite Capital Management IV, LLC | 1,787,094 | $8,113,000 | 0.97% |
| Avoro Capital Advisors LLC | 10,300,000 | $46,762,000 | 0.81% |
| Boxer Capital, LLC | 4,000,000 | $18,160,000 | 0.62% |
| Sio Capital Management, LLC | 562,339 | $2,553,000 | 0.52% |
| ACUTA CAPITAL PARTNERS, LLC | 315,341 | $1,432,000 | 0.52% |
| CM Management, LLC | 150,000 | $681,000 | 0.51% |
| APIS CAPITAL ADVISORS, LLC | 120,000 | $545,000 | 0.50% |
| Versant Venture Management, LLC | 543,753 | $2,469,000 | 0.48% |